Clinical Trials Sponsored by Minneamrita Therapeutics LLC

Total 407 results

Rise Therapeutics LLC

Recruiting

R-5280 in Newly Diagnosed Patients With Type 1 Diabetes (R-5280)

Diabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes (Juvenile Onset)

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Recruiting

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Healthy Participants | Alzheimer's Disease Dementia

United States
Cloudbreak Therapeutics, LLC

Recruiting

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

Pinguecula

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Poland, Spain, Serbia, Australia, Ukraine
Cerevel Therapeutics, LLC

Enrolling by invitation

Open-label Trial in Parkinson's Disease (PD) (TEMPO-4)

Parkinson Disease

Poland, United States, Spain, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Serbia, Ukraine
Cerevel Therapeutics, LLC

Active, not recruiting

Flexible-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-2)

Parkinson Disease

Poland, Spain, United States, France, Germany, Hungary, Italy, Serbia, Ukraine, Australia, Korea, Republic of, Taiwan, Thailand
Cerebral Therapeutics LLC

Terminated

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

Focal Epilepsy

Israel, Australia
Grifols Therapeutics LLC

Active, not recruiting

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (SPARTA)

Pulmonary Emphysema in Alpha-1 PI Deficiency

United States, Australia, Denmark, New Zealand, Estonia, Poland, Russian Federation, Sweden, Brazil, Canada, France, Finland
TerSera Therapeutics LLC

Completed

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine (versus)

Oncology Patients Receiving Chemotherapy

United States
RSV Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

SARS-CoV-2 Infection

Russian Federation
TerSera Therapeutics LLC

Terminated

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer (TELE-ABC)

Biliary Tract Cancer (BTC)

United States
LIB Therapeutics LLC

Completed

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (LIBerate-H2H)

Cardiovascular Diseases | Hypercholesterolemia

United States
LIB Therapeutics LLC

Completed

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Homozygous Familial Hypercholesterolemia

United States, Israel, Norway, South Africa, Turkey, India
Homeostasis Therapeutics, LLC

Completed

Modified Ketogenic Diet and Ketamine for Anorexia Nervosa

Anorexia Nervosa

United States
Lenus Therapeutics, LLC

Terminated

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (CELEB)

Dystrophic Epidermolysis Bullosa | Junctional Epidermolysis Bullosa

United States
TerSera Therapeutics LLC

Completed

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO (RELAX)

Carcinoid Syndrome

United States
Cerevel Therapeutics, LLC

Completed

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Healthy

United States
Cerevel Therapeutics, LLC

Completed

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Allodynic Therapeutics, LLC

Completed

Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)

Chronic Low Back Pain | Lumbar Radiculopathy

United States
Allodynic Therapeutics, LLC

Completed

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine (ANODYNE-1)

Migraine With or Without Aura

United States
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
Valerion Therapeutics, LLC

Terminated

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

Pompe Disease

United States, United Kingdom
Grifols Therapeutics LLC

Withdrawn

Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States
Grifols Therapeutics LLC

Completed

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Belgium, Czechia, Estonia, Canada, France, Germany, Hungary, Poland, Lithuania
Trius Therapeutics LLC

Completed

Microdialysis and Pharmacokinetic Study of TR-701

Healthy

United States
Trius Therapeutics LLC

Completed

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Bacterial Infection
Trius Therapeutics LLC

Completed

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Healthy Volunteer

United States
Olatec Therapeutics LLC

Completed

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

Pain | Osteoarthritis

United States
Trius Therapeutics LLC

Completed

A Phase 1, Open-Label, 10 Day Safety Study

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (IV/SAD/MAD)

Bacterial Infections

United States
Trius Therapeutics LLC

Completed

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

Healthy Volunteers

United States
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ICE)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, Israel, Germany, Czech Republic, Mexico, Argentina, Canada, Italy, Poland, Serbia
Grifols Therapeutics LLC

Completed

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States
Grifols Therapeutics LLC

Completed

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Acute Ischemic Stroke

Spain, Australia, France, Austria, Serbia, Slovakia
Grifols Therapeutics LLC

Completed

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients (CF2)

Cystic Fibrosis
Grifols Therapeutics LLC

Completed

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Rabies

United States
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency (SPARK)

Emphysema | Alpha 1-antitrypsin Deficiency (AATD)

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Common Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency Syndrome

Canada, United States
PHARMENTERPRISES LLC
RSV Therapeutics LLC

Completed

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

Influenza | Acute Respiratory Viral Infections

Russian Federation
Melinta Therapeutics, LLC

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Gram Positive Bacterial Infections

United States
Melinta Therapeutics, LLC

Recruiting

Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin

Acute Bacterial Skin and Skin Structure Infection

United States, Spain, Greece, Portugal, Bulgaria, Latvia, Romania, Lithuania, Poland
Cancer Insight, LLC
Elios Therapeutics, LLC

Completed

Phase IIB TL + YCWP + DC in Melanoma

Melanoma

United States
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Completed

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
10xBio, LLC
Therapeutics, Inc.

Active, not recruiting

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

Subcutaneous Fat Disorder

United States
Vitrac Therapeutics, LLC
Westat

Terminated

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
PrECOG, LLC.
Celldex Therapeutics

Terminated

Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung (PrE0504)

Squamous Cell Carcinoma of the Lung

United States

Clinical Trials Sponsored by Minneamrita Therapeutics LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations